Friday, 18 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 2, 2026

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

View original at finance.yahoo.com
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be hi…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The EHA data presentations represent a significant moment for Lilly's hematology ambitions.

    60% confidence

  • Lilly has a relentless commitment to pursue meaningful advancements for people living with blood disorders.

    60% confidence

  • The Phase 3 BRUIN CLL-322 results address an important question for patients with relapsed or refractory CLL, demonstrating that time-limited pirtobrutinib can meaningfully improve outcomes when added to an already effective venetoclax-based regimen.

    60% confidence

  • Pirtobrutinib plus venetoclax and rituximab produced positive results versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL in the Phase 3 BRUIN CLL-322 study.

    60% confidence

  • AJ1-11095 is a first-in-class type II JAK2 inhibitor for patients with myelofibrosis who have been failed by a type I JAK2 inhibitor.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Industry Reckoning: Safety Warnings Collide With Slowdown-Driven Market Jitters
A wave of high-profile safety concerns — Dario Amodei's call for a global slowdown in frontier AI development, Microsoft's humanist AI code of conduct, and researcher departures from Anthropic and Google citing safety risks — is converging with investor unease, as seen in GE Vernova's 8.6% stock drop on the slowdown call and Palantir's 6% decline. The narrative reflects growing tension between rapid AI commercialization and mounting governance, safety, and market-sustainability concerns.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,297 source documents archived
Query this data → isubstrate.com